Literature DB >> 9950892

Variable expression of endothelial NO synthase in three forms of rat pulmonary hypertension.

R C Tyler1, M Muramatsu, S H Abman, T J Stelzner, D M Rodman, K D Bloch, I F McMurtry.   

Abstract

Endothelial nitric oxide (NO) synthase (eNOS) mRNA and protein and NO production are increased in hypoxia-induced hypertensive rat lungs, but it is uncertain whether eNOS gene expression and activity are increased in other forms of rat pulmonary hypertension. To investigate these questions, we measured eNOS mRNA and protein, eNOS immunohistochemical localization, perfusate NO product levels, and NO-mediated suppression of resting vascular tone in chronically hypoxic (3-4 wk at barometric pressure of 410 mmHg), monocrotaline-treated (4 wk after 60 mg/kg), and fawn-hooded (6-9 mo old) rats. eNOS mRNA levels (Northern blot) were greater in hypoxic and monocrotaline-treated lungs (130 and 125% of control lungs, respectively; P < 0.05) but not in fawn-hooded lungs. Western blotting indicated that eNOS protein levels increased to 300 +/- 46% of control levels in hypoxic lungs (P < 0.05) but were decreased by 50 +/- 5 and 60 +/- 11%, respectively, in monocrotaline-treated and fawn-hooded lungs (P < 0.05). Immunostaining showed prominent eNOS expression in small neomuscularized arterioles in all groups, whereas perfusate NO product levels increased in chronically hypoxic lungs (3.4 +/- 1.4 microM; P < 0.05) but not in either monocrotaline-treated (0.7 +/- 0.3 microM) or fawn-hooded (0.45 +/- 0.1 microM) lungs vs. normotensive lungs (0.12 +/- 0.07 microM). All hypertensive lungs had increased baseline perfusion pressure in response to nitro-L-arginine but not to the inducible NOS inhibitor aminoguanidine. These results indicate that even though NO activity suppresses resting vascular tone in pulmonary hypertension, there are differences among the groups regarding eNOS gene expression and NO production. A better understanding of eNOS gene expression and activity in these models may provide insights into the regulation of this vasodilator system in various forms of human pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9950892     DOI: 10.1152/ajplung.1999.276.2.L297

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  27 in total

1.  Idiopathic pulmonary arterial hypertension: an avian model for plexogenic arteriopathy and serotonergic vasoconstriction.

Authors:  Robert F Wideman; Krishna R Hamal
Journal:  J Pharmacol Toxicol Methods       Date:  2011-01-26       Impact factor: 1.950

2.  Intermittent hypoxia augments pulmonary vascular smooth muscle reactivity to NO: regulation by reactive oxygen species.

Authors:  Charles E Norton; Nikki L Jernigan; Nancy L Kanagy; Benjimen R Walker; Thomas C Resta
Journal:  J Appl Physiol (1985)       Date:  2011-07-14

3.  Abnormal expression of NSF, α-SNAP and SNAP23 in pulmonary arterial hypertension in rats treated with monocrotaline.

Authors:  Hong-Liang Zhang; Zhi-Hong Liu; Qin Luo; Yong Wang; Zhi-Hui Zhao
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 4.  Nitrite in pulmonary arterial hypertension: therapeutic avenues in the setting of dysregulated arginine/nitric oxide synthase signalling.

Authors:  Brian S Zuckerbraun; Patricia George; Mark T Gladwin
Journal:  Cardiovasc Res       Date:  2010-12-22       Impact factor: 10.787

Review 5.  The structural basis of pulmonary hypertension in chronic lung disease: remodelling, rarefaction or angiogenesis?

Authors:  Natalie Hopkins; Paul McLoughlin
Journal:  J Anat       Date:  2002-10       Impact factor: 2.610

6.  Mechanisms underlying the impairment of endothelium-dependent relaxation in the pulmonary artery of monocrotaline-induced pulmonary hypertensive rats.

Authors:  H Nakazawa; M Hori; H Ozaki; H Karaki
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

7.  Changes in functional and histological distributions of nitric oxide synthase caused by chronic hypoxia in rat small pulmonary arteries.

Authors:  Mikiyasu Shirai; James T Pearson; Akito Shimouchi; Noritoshi Nagaya; Hirotsugu Tsuchimochi; Ishio Ninomiya; Hidezo Mori
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

8.  Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice.

Authors:  You-Yang Zhao; Yang Liu; Radu-Virgil Stan; Lian Fan; Yusu Gu; Nancy Dalton; Po-Hsien Chu; Kirk Peterson; John Ross; Kenneth R Chien
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

9.  Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat.

Authors:  Vincent G DeMarco; Javad Habibi; Adam T Whaley-Connell; Rebecca I Schneider; James R Sowers; Bradley T Andresen; Alex A Gutweiler; Lixin Ma; Megan S Johnson; Carlos M Ferrario; Kevin C Dellsperger
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-07-24       Impact factor: 4.733

10.  Golgi, trafficking, and mitosis dysfunctions in pulmonary arterial endothelial cells exposed to monocrotaline pyrrole and NO scavenging.

Authors:  Jason Lee; Reuben Reich; Fang Xu; Pravin B Sehgal
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-07-31       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.